Altogether, we show that selection of CD39– Tim3– Slamf6+ PD-1+ TILs enables enrichment of tumor specific Tcf1+ PD-1+ TILs Tpe that may enhance efficacy of adoptive cell transfer therapies in cancer patients. This evidence concerns the gene SLAMF6 and neoplasm.